3B Scientific GmbH

Based in Germany, 3B Scientific GmbH offers advanced medical simulation products and training solutions designed to enhance clinical education and improve healthcare professionals' skills through immersive and realistic training environments. 3B Scientific GmbH specializes in medical simulation and training solutions. Founded in 1948 in Hamburg, Germany, the company has undergone significant transformation, including its recent acquisition by G Square in June 2022. The current CEOs are Carsten Erpel and Todd Murray.

The company has completed three deals, with the most recent deal occurring on June 17, 2022. 3B Scientific specializes in providing advanced medical simulation and task trainers designed for clinical education. The company's core product offerings include a diverse range of simulation equipment and training solutions aimed at enhancing the skills of healthcare professionals. Key products feature immersive rooms that simulate real-life healthcare environments, allowing users to engage in scenario-based learning and practice essential clinical skills in a controlled setting.

Other notable offerings include the Atlas family of airway management training devices, which cater to emergency and prehospital care scenarios. These products are used primarily by hospitals, medical schools, and training centers, especially in markets such as Germany, North America, Japan, and across Europe, where there is a growing demand for innovative training solutions in healthcare. 3B Scientific generates revenue primarily through direct sales of its medical simulation products and training services to healthcare institutions and educational establishments. Transactions typically occur via B2B partnerships, where institutions purchase equipment and training modules tailored to their specific educational needs.

The company’s flagship products, such as the Atlas airway management trainers, are critical to its revenue stream, with institutions engaging in bulk purchases or subscription models for ongoing access to training resources. In 2023, the company reported an EBITDA of USD 3,664,028. 8, reinforcing its position in the medical education sector. 3B Scientific is focused on expanding its product offerings and entering new markets.

Plans include the development of new simulation products designed to enhance training for healthcare professionals, with anticipated releases in the upcoming year. The company also aims to expand its reach into additional regions beyond its current strongholds, specifically targeting markets in Asia and Latin America by 2025. The recent acquisition in June 2022 will provide the necessary capital to support these growth initiatives, enabling 3B Scientific to enhance its product development and expand into new geographic areas.